[关键词]
[摘要]
巩膜交联术(SXL)作为一种通过增强巩膜胶原纤维机械强度以延缓近视进展的技术,在近视防控领域展现出重要潜力。目前,动物实验已证实 SXL 可有效提升豚鼠、兔、猪等模型的巩膜生物力学性能,且显著抑制眼轴异常增长,其作用机制主要基于调控胶原合成与降解相关基因,改善巩膜重塑。现有的研究中,核黄素/紫外线A光化学交联及京尼平等化学交联剂注射的方式各有优势,新型递送系统(如集成微针给药、μ-LED 光照及超声调控的无线贴片)进一步实现了精准化、微创化治疗,且巩膜区域特性导致的疗效差异提示个体化治疗的必要性。尽管当前研究面临长期安全性、儿童群体适配性、方案标准化等挑战,但 SXL 为近视(尤其是病理性近视)的防控提供了全新思路,未来通过优化药物递送技术、研发新型器械及无创监测手段,有望推动其临床转化,为控制近视进展、减少并发症提供有效手段。
[Key word]
[Abstract]
Scleral cross-linking(SXL), a technique that enhances the mechanical strength of scleral collagen fibers to slow myopia progression, has shown considerable potential in the field of myopia prevention and control. To date, animal studies have demonstrated that SXL can effectively improve the scleral biomechanical properties in guinea pig, rabbit, and porcine models, while significantly inhibiting abnormal axial elongation. Its therapeutic effects are mainly attributed to the regulation of genes involved in collagen synthesis and degradation, thereby improving scleral remodeling. Current approaches include riboflavin/ultraviolet A photochemical cross-linking and chemical cross-linking using agents such asgenipin, each with distinct advantages. Novel delivery systems, including wireless patches integrating microneedle drug delivery, μ-LED illumination, and ultrasonic regulation, have further enabled more precise and minimally invasive treatment. In addition, variations in treatment efficacy associated with regional characteristics in sclera properties highlight the need for individualized therapeutic strategies. Although several challenges remain, including long-term safety, applicability in pediatric populations, and standardization of protocols, SXL offers a novel approach for myopia control, particularly in pathological myopia. Future advances in drug-delivery technologies, innovative devices, and non-invasive monitoring methods are expected to facilitate its clinical translation and provide an effective strategy for controlling myopia progression and reducing associated complications.
[中图分类号]
[基金项目]
国家自然科学基金项目(No.82460203); 国家重点研发项目(No.2025YFA1212700,2025YFA1212702)